BerGenBio appoints Dr Sue Foden to board
This article was originally published in Scrip
BerGenBio, a Norwegian oncology biopharma company, has appointed Dr Sue Foden to its board of directors. Dr Foden was one of the founders of Cancer Research UK and also served as CEO of Cancer Research Campaign Technology and Cancer Research Ventures. She was an advisor on several EU projects, and is currently a director of Source Bioscience, Elara and Vectura.